Prithviraj Bose1, Srdan Verstovsek2. 1. Department of Leukemia, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, FC4.3062, Unit 428, Houston, TX, 77030, USA. pbose@mdanderson.org. 2. Department of Leukemia, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, FC4.3062, Unit 428, Houston, TX, 77030, USA.
Abstract
PURPOSE OF REVIEW: Cytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest efficacy and ruxolitinib, the only approved drug for myelofibrosis, is myelosuppressive. Yet, dose optimization of ruxolitinib is important for its survival benefit in patients with advanced disease. We sought to summarize the data on treatments for cytopenias available at present and review promising agents in development and emerging strategies. RECENT FINDINGS: The activin receptor ligand traps hold considerable promise for the treatment of anemia and could represent an attractive combination strategy with ruxolitinib. Low-dose thalidomide, which could offset both anemia and thrombocytopenia caused by ruxolitinib, represents another potential partner for ruxolitinib. The anti-fibrotic agent PRM-151 produced sustained improvements in cytopenias in some patients, and further data on this drug are eagerly awaited. Finally, several preclinical leads with translational potential are worthy of clinical investigation as strategies to halt/reverse bone marrow fibrosis and thereby improve cytopenias. Cytopenias remain a significant hurdle in myelofibrosis management, but several novel investigational agents hold considerable promise for the future.
PURPOSE OF REVIEW: Cytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest efficacy and ruxolitinib, the only approved drug for myelofibrosis, is myelosuppressive. Yet, dose optimization of ruxolitinib is important for its survival benefit in patients with advanced disease. We sought to summarize the data on treatments for cytopenias available at present and review promising agents in development and emerging strategies. RECENT FINDINGS: The activin receptor ligand traps hold considerable promise for the treatment of anemia and could represent an attractive combination strategy with ruxolitinib. Low-dose thalidomide, which could offset both anemia and thrombocytopenia caused by ruxolitinib, represents another potential partner for ruxolitinib. The anti-fibrotic agent PRM-151 produced sustained improvements in cytopenias in some patients, and further data on this drug are eagerly awaited. Finally, several preclinical leads with translational potential are worthy of clinical investigation as strategies to halt/reverse bone marrow fibrosis and thereby improve cytopenias. Cytopenias remain a significant hurdle in myelofibrosis management, but several novel investigational agents hold considerable promise for the future.
Authors: Kebede H Begna; Animesh Pardanani; Ruben Mesa; Mark R Litzow; William J Hogan; Curtis A Hanson; Ayalew Tefferi Journal: Am J Hematol Date: 2011-11-12 Impact factor: 10.047
Authors: Robert Weinkove; John T Reilly; Mary Frances McMullin; Natasha J Curtin; Deepti Radia; Claire N Harrison Journal: Haematologica Date: 2008-05-27 Impact factor: 9.941
Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: John O Mascarenhas; Moshe Talpaz; Vikas Gupta; Lynda M Foltz; Michael R Savona; Ronald Paquette; A Robert Turner; Paul Coughlin; Elliott Winton; Timothy C Burn; Peter O'Neill; Jason Clark; Deborah Hunter; Albert Assad; Ronald Hoffman; Srdan Verstovsek Journal: Haematologica Date: 2016-10-27 Impact factor: 9.941
Authors: Carole B Miller; Rami S Komrokji; Ruben A Mesa; William Sun; Michael Montgomery; Srdan Verstovsek Journal: Clin Lymphoma Myeloma Leuk Date: 2017-05-12
Authors: Qiang Jeremy Wen; Qiong Yang; Benjamin Goldenson; Sébastien Malinge; Terra Lasho; Rebekka K Schneider; Lawrence J Breyfogle; Rachael Schultz; Laure Gilles; Priya Koppikar; Omar Abdel-Wahab; Animesh Pardanani; Brady Stein; Sandeep Gurbuxani; Ann Mullally; Ross L Levine; Ayalew Tefferi; John D Crispino Journal: Nat Med Date: 2015-11-16 Impact factor: 53.440
Authors: C N Harrison; A M Vannucchi; J-J Kiladjian; H K Al-Ali; H Gisslinger; L Knoops; F Cervantes; M M Jones; K Sun; M McQuitty; V Stalbovskaya; P Gopalakrishna; T Barbui Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528